Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Baghbanian, Mahmud; Halvani, Mehdi; Roghani, H Salman; Lotfi, Mohammad Hassan; Yazdi, Mohammad Frahat; Vahedian, Hasanali

doi:10.1590/s0004-28032016000300010

Cited by 10 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In immunocompromised patients for oncological pathology, the data are fragmentary. In a study carried out in Iran on many cancer patients, the prevalence of OBI in this study was 4.4% (out of 204) 67 . Sodhi et al 68 estimated that OBI incidence among 244 HBsAg‐negative cancer patients before receiving chemotherapy was 1.9% (13 out of 690).…”

Section: Prevalence Of Obi In Western Countriesmentioning

confidence: 45%

“…In a study carried out in Iran on many cancer patients, the prevalence of OBI in this study was 4.4% (out of 204). 67 Sodhi et al 68 estimated that OBI incidence among 244 HBsAg-negative cancer patients before receiving chemotherapy was 1.9% (13 out of 690). In another study by Cheung et al, 69 where 47 lymphoma patients were studied, 10 out of 47 (21%) had OBI.…”

Section: Search Strategymentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of occult HBV infection in Western countries

Pisaturo

Onorato

Russo

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Due to a lack of standardized tests, it is difficult to obtain prevalence data and define the real impact of occult HBV infection (OBI) in Western countries. The present review article addresses the prevalence of OBI, defined as presence of hepatitis B virus (HBV) DNA in liver tissue or plasma in HBsAg‐negative subjects, in Western countries. This varies in different studies according to the different methodologies used (based on serology vs virology), to the sample analyzed for the diagnosis (liver tissue vs plasma), to the different populations studied, to the different geographical variations in the HBV spread, to the host characteristics (age, gender, risk factors for acquiring HBV infection) and to the presence of other parenteral infections (hepatitis C virus and/or human immunodeficiency virus [HIV] infections). Considering the different liver diseases analyzed, that is in patients with cryptogenic cirrhosis or advanced liver fibrosis, the prevalence of OBI ranges 4% to 38%. Considering the different populations studied, in the case of parenteral blood exposure it is about 45%, in patients with chronic hepatitis C it is estimated at about 52%, in HIV‐infected patients it ranges from 0% to 45%, in blood donors from 0% to 22.7% and in hemodialysis patients it ranges from 0% to 54%. In conclusion, OBI is a virological entity to be considered when performing the patient's evaluation for immunosuppressive diseases, liver pathologies, or for blood transfusions. Knowing the prevalence and clinical impact of OBI will allow better patient management.

show abstract

Section: Prevalence Of Obi In Western Countriesmentioning

confidence: 45%

Section: Search Strategymentioning

confidence: 99%

Prevalence of occult HBV infection in Western countries

Pisaturo

Onorato

Russo

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Patients with hematologic malignancy had a higher incidence of occult hepatitis B compared to the group with solid organ malignancy. There was no significant difference between anti-HBc IgG positivity and frequent blood transfusions, familial hepatitis and biochemical parameters (AST, ALT) (p > 0.05) [16].…”

Section: Discussionmentioning

confidence: 80%

Hepatitis B seroprevalence in hematological oncology patients

Türken

Köse

Acar

et al. 2020

The European Research Journal

View full text Add to dashboard Cite

Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluated retrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxis in patients with hematological malignancy. Methods: A total of 499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBV DNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) with Real-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated by SPSS for Windows 15.00 statistical program. A value of p <0.05 was accepted as a statistical significance value. Results: HBsAg positivity was found to be 3.4% (n = 17) in all patients. Appropriate treatment regimens were started to patients with HBsAg (+). There were 166 (33.3%) patients with anti-HBs (+). One hundred nineteen (23.8%) patients had anti-HBc IgG (+), 40 (33.6%) of them were started a prophylactic treatment regimen. Anti-HBs positivity were reported after vaccination in 48 (16.8%) patients. Occult hepatitis have not been detected in patients with anti-HBc IgG positivity. Conclusions: As a result of this study, anti-HBs negative patients with hematological malignancies were vaccinated. Patients and physicians should be informed about vaccination and hepatitis serology controls of hematological malignancy and other immunosuppressed patients. Sensitivity in this context should be increased in terms of prophylactic treatments.

show abstract

“…The 20-34 age group was the largest in terms of the number of participants in our study, as was the case in the study conducted by Oluyinka and al. However, the 30-60 age group was the most important in the studies conducted by Kalantari and al, and Baghbanian and al, on the prevalence of OBI in hemodialysis patients and cancer patients in Iran [25, 26].…”

Section: Discussionmentioning

confidence: 99%

Biological diagnosis and characterization of occult hepatitis B virus infection in Burkina Faso

Doumbia

Diarra²,

Kone

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction/objective: The occult infection by the hepatitis B virus (OBI) characterized by the undetectable (HBs Ag) negative antigen in the serum and the presence of viral DNA, constitutes a major public health problem and a major challenge for clinical forms of hepatitis worldwide. The persistence of OBI very often leads to hepatocellular carcinoma (HCC) and immunodeficiency. The aim of this study was to estimate the prevalence of OBI and to characterize the incriminated genotypes of the virus.Material and method: The plasmas of 252 HBsAg-negative volunteers were used for highlighting the viral DNA by PCR classic. PCR Multiplex using specific primers of 6 genotypes (A to F) was used for characterization. Results: A prevalence of 11.9% (30/252) of OBI was obtained with 7.5% in women and 4.4% for men. Genotypes E (60.0%) and A3 (23.3%) were present and genotypes B, C, D, and F were absent. A mixed infection with E/A3 genotypes (16.7%) was observed. AC Anti-HBc was present in 80% of cases OBI.Discussion/Conclusion: The prevalence of 11.9% of OBI could be related to the level of endemicity of the study area, Burkina Faso being a country with a prevalence of more than 14% of HBV infection. These infections are dominated by the A3 and E genotypes, confirming their importance in chronic HBV infections. The absence of genotypes B and C in cases of OBI constitutes a positive predictive value since their presence is linked to a more rapid evolution of the infection towards HCC.

show abstract

Prevalence of Occult Hepatitis B Infection in Iranian Cancer Patients Before Chemotherapy Treatment

Cited by 10 publications

References 38 publications

Prevalence of occult HBV infection in Western countries

Prevalence of occult HBV infection in Western countries

Hepatitis B seroprevalence in hematological oncology patients

Biological diagnosis and characterization of occult hepatitis B virus infection in Burkina Faso

Contact Info

Product

Resources

About